The KCL039 human embryonic stem cell line was derived from a normal healthy blastocyst donated for research. The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin fibroblasts. Both the derivation and cell line propagation were performed in an animal product-free environment and under current Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were confirmed by in vitro assays.
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We generated a KCL039 clinical grade hESC line following protocols, established previously Stephenson et al., 2012) , and now adapted to cGMP conditions. The expression of the pluripotency markers was tested after a freeze/thaw cycle (Fig. 1) . Differentiation potential into three germ layers was verified in vitro (Fig. 2) .
The embryo donors were negative for Human Immunodeficiency Virus 1/2 (HIV1/2), Hepatitis B (HepB, HCB) and C Virus (HepC, HCV). We did not retest the line.
We also generated a research grade of the KCL039 line that is adapted to feeder-free conditions.
Materials and methods

Consenting process
We distributed patient information sheets (PIS) and consent forms to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent forms were mailed to them. If in the meantime new versions of PIS/ consent forms are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (FRO-V.10) were created on Sep. 19, 2011. The HFEA Code of Practice that was in effect at the time of document creation was: Edition 8 -R.3 (http://www.hfea. gov.uk/2999.html). The donor couple signed the consent on Nov. 15, 2011. The HFEA Code of Practice that was in effect at the time of donor signature was: Edition 8 -R.4. The HFEA Code of Practice Edition 8 -R.3 was in effect from Apr. 07, 2011 to Oct. 01, 2011, whereas 8 -R.4 was in effect from Oct. 02, 2011 to Apr. 02, 2012.
Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details Stephenson et al., 2012) . The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).
Cell culture
ICM plated on mitotically inactivated HFF were cultured as previously described Stephenson et al., 2012) . Trophectoderm cells were removed mechanically from outgrowth (Ilic et al., 2007; Ilic et al., 2010) . hESC colonies were expanded and cryopreserved at the third passage.
Viability test
Straws with the earliest frozen passage (p. 2-3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were partly frozen and partly subjected to a standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, and mycoplasma). Fig. 1 . Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress fibers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm. 
Pluripotency
Pluripotency in vitro was assessed using two different techniques: enzymatic activity assay [alkaline phosphatase (AP) assay] and immunostaining as previously described Stephenson et al., 2012) .
Differentiation
Spontaneous differentiation into three germ layers was assessed in vitro as previously described (Petrova et al., 2014; Stephenson et al., 2012) .
Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA extraction robot according to the manufacturer's instructions. Amplification of polymorphic microsatellite markers was carried out as previously described . Allele sizes were recorded to give a unique fingerprint of each cell line.
Array comparative genomic hybridization (aCGH) aCGH was performed as described in detail by Ilic et al. (2012) .
Whole-genome single nucleotide polymorphism (SNP) array SNP array was performed as described in detail by Canham et al. (2015) .
HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequencespecific oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybridization protocol at the certified Clinical Transplantation Laboratory, Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pathology (Guy's Hospital, London, UK) as previously described (Jacquet et al., 2013) . HLA typing was also performed independently by another group (Canham et al., 2015) .
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